FDA Biologics (BLA & Biosimilars)Original article
Vaccines and Related Biological Products Advisory Committee June 18, 2026 Meeting Announcement - 06/18/2026
AdComMFLUSIVANeutral
AI Analysis
Summary
FDA's Vaccines and Related Biological Products Advisory Committee will meet on June 18, 2026 to discuss and make recommendations on the safety and effectiveness of MFLUSIVA, a vaccine for the prevention of influenza A and B in persons 50 years of age and older (BLA STN 125869/0).
Outcome Details
Vaccines and Related Biological Products Advisory Committee meeting to discuss and make recommendations on safety and effectiveness
Importance:7/10
Sentiment:
0.00
Influenza vaccineBLAAdvisory CommitteeAge 50+FDA
Read the original article
Published by FDA Biologics (BLA & Biosimilars) on September 23, 2026 2:31 PM